Clinical Trial

Study on Gene Evolution in Glioma Under Stress Therapy

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 27, 2022 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Little is known about the evolution of genetic and epigenetic changes that occur in the progression of glioma. We inferred the evolution trajectories of matched pairs of primary tumors and progression tumor in situ fluid (TISF) based on deep whole-genome-sequencing data (ctDNA). A monocentric, Gene grouping controlled trial design was used to select patients. and to compare gene evolution of different subtypes of glioma under therapy. To predict the molecular reaction of bevacizumab treatment, clarify the mechanism of drug resistance of bevacizumab treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-08-21.
Status change: Recruiting → Not Yet Recruiting 2022-09-25
Trial Details
NCT Number NCT05512325
Lead Sponsor Henan Provincial People's Hospital
Conditions Genetic Change
Enrollment 100 participants
Start Date 2022-12-17
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2022-09-27